Paradigm Biopharmaceuticals presents novel six-month data in its PARA_OA_008 Phase II clinical study

Paradigm Biopharmaceuticals (ASX: PAR) is a late-stage drug development company that is driven to improve patients’ health and quality of life by discovering, developing and delivering pharmaceutical therapies. Paradigm’s current focus is on developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue-regenerative properties of PPS, such as in osteoarthritis (Phase III) and mucopolysaccharidosis (Phase II).
We recently held a webinar with Paradigm to discuss the Phase II six-month data from its knee osteoarthritis trial, addressing iPPS’s effect on biomarkers such as pain, knee function and disease modification. The webinar is hosted by Edison’s Soo Romanoff and includes updates from Paradigm’s Paul Rennie (founder, managing director and chair) Donna Skerrett MD (chief medical officer) and Mukesh Ahuja (global head of OA).